Jove
Visualize
Contact Us

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Purine Salvage Promotes Treatment Resistance In H3k27m-mutant Diffuse Midline Glioma.
  1. Home
  3. Purine Salvage Promotes Treatment Resistance In H3k27m-mutant Diffuse Midline Glioma.

Related Experiment Video

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

16.9K

Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma.

Erik R Peterson1,2,3, Peter Sajjakulnukit1,3, Andrew J Scott2,3

  • 1Doctoral Program in Cancer Biology, University of Michigan, Ann Arbor, MI, USA.

Cancer & Metabolism
|April 9, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Diffuse midline gliomas (DMG) with H3K27M mutations exhibit altered purine metabolism. Inhibiting purine salvage pathways, alongside radiation, shows promise in overcoming treatment resistance in these aggressive brain tumors.

Keywords:
Diffuse midline gliomaH3K27MPurine metabolismRadiation therapy resistance

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.5K
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

12.9K

Related Experiment Videos

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

16.9K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.5K
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

12.9K

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Epigenetics

Background:

  • Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are aggressive brain tumors often driven by H3K27M mutations.
  • These tumors exhibit altered metabolism and resistance to standard radiation therapy (RT).
  • The precise mechanisms by which H3K27M mutations mediate metabolic responses to radiation and treatment resistance remain unclear.

Purpose of the Study:

  • To investigate the role of purine synthesis pathways in the metabolic response of DMG-H3K27M cells to radiation.
  • To evaluate the therapeutic potential of targeting purine synthesis in combination with RT for DMG-H3K27M.

Main Methods:

  • Metabolomics and stable isotope tracing were performed on irradiated and untreated DMG-H3K27M cell lines.
  • Purine synthesis enzyme expression was profiled in patient data and cell models.
  • In vitro and in vivo studies assessed the response to RT combined with inhibition of de novo and salvage purine synthesis.

    • Main Results:

    • DMG-H3K27M cells showed H3K27M-specific enrichment in purine synthesis pathways, with higher de novo synthesis and lower salvage activity.
    • Inhibition of de novo guanylate synthesis radiosensitized DMG-H3K27M cells.
    • Irradiated cells upregulated salvage pathways, and exogenous guanine supplementation reduced radiosensitization.
    • Silencing HGPRT combined with RT significantly suppressed tumor growth in vivo.

    Conclusions:

    • DMG-H3K27M cells depend on both de novo and salvage purine synthesis.
    • Active salvage pathways can bypass inhibition of de novo synthesis.
    • Inhibiting purine salvage presents a potential strategy to overcome treatment resistance in DMG-H3K27M tumors.